Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial
Journal of clinical hypertension (Greenwich, Conn.), 2018.
Hypertension-generalantihypertensive therapyclinical management of high blood pressure (HBP)clinical trialscombination therapy
Patients with grade 2-3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160-190 mm Hg and 24-hour SBP 140-175 mm Hg by ambulatory blood pressure monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL-M) monotherapy for 4 weeks. "Nonresponders" were then randomized to 8 weeks of double-blind treatment w...More
Full Text (Upload PDF)
PPT (Upload PPT)